(EVGN) Evogene Ltd. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
Make Smarter Strategic Decisions with a Complete PESTEL View
This Evogene Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces may impact the company and is useful for investors, strategists, and researchers. The page contains a real preview/sample of the report so you can judge style and depth—purchase the full version to receive the complete, ready-to-use analysis.
Political factors
4 operating geographies: Israel, United States, Brazil and other markets
Evogene Ltd. operates across 4 geographies, including Israel, the United States, Brazil and other markets, so it faces 3 different policy tracks: biotech, agriculture and healthcare. A rule change in one market can delay trial approvals, slow partnerships and push out commercialization dates. Cross-border work also raises exposure to sanctions, trade frictions and supply-chain shocks.
1999-founded Israeli company with life-science R&D exposure
Israel’s innovation policy supports Evogene Ltd.’s R&D model: OECD data show Israel spends about 6.3% of GDP on R&D, the highest in the group. Tax credits, grants, and government-backed research support can lower development costs, but the country’s security risks can still disrupt staffing, logistics, and lab continuity. For an R&D-heavy company, execution risk matters.
Agricultural biotech linked to public food-security policy
National agriculture policy drives demand for Evogene Ltd.’s seed traits, crop chemicals and biologicals because yield and resilience targets shape what farmers buy. OECD says farm support across 54 countries reached about USD 842 billion in 2023, so public funding can move markets fast. If food-security rules and procurement favor sustainable inputs, Evogene’s products can gain faster adoption.
Partnership-driven model with BASF, Corteva and Bayer
Evogene Ltd.'s BASF, Corteva and Bayer partnerships sit in markets shaped by farm rules, trade limits and licensing laws across many countries. Political shifts can change who can sell, where joint products can launch, and how much scope each partner gets. The model works best when regulation stays stable; in 2025, global agri trade still faced new tariff and biotech-review friction.
- Policy can narrow licensing rights.
- Trade rules can block market access.
- Stable regulation supports partner ROI.
Medical cannabis activity in regulated markets
Cannabis stays politically sensitive and tightly controlled, so a shift in government stance can change licensing, distribution, and product acceptance fast. That creates both upside and policy risk for Evogene Ltd. Canonic and Cannbit collaborations, especially where regulators can pause or widen access overnight.
In regulated markets such as Israel and Germany, market access depends on permits, GMP compliance, and import rules, so approvals are never fixed. A friendlier policy can speed rollout and revenue, but a stricter one can delay launches and cut partner sales.
- Policy shifts can reprice access fast.
- Licenses and distribution are government-led.
- Canonic and Cannbit face both upside and risk.
Evogene Faces Policy-Driven Growth Risks Across Global Markets
Evogene Ltd. is highly exposed to policy shifts because its R&D, agri-tech, and cannabis work depends on permits, trade rules, and product approvals across Israel, the United States, Brazil, and Europe. Israel’s 6.3% R&D spend supports its innovation base, but security and regulatory shocks can still delay labs, trials, and partner launches. In 2025, agri trade and biotech review friction kept market access uneven.
| Political factor | Latest data |
|---|---|
| Israel R&D intensity | 6.3% of GDP |
| Global farm support | USD 842bn in 2023 |
| Key risk | Approvals and licenses |
What is included in the product
Detailed Word Document
Analyzes how political, economic, social, technological, environmental, and legal forces shape Evogene Ltd.’s risks, opportunities, and strategy.
Customizable Excel Spreadsheet
A concise, organized Evogene Ltd. PESTLE snapshot that makes external risks and opportunities easy to review at a glance.
Reference Sources
Cites primary industry reports, patents, company filings, and peer‑reviewed studies to fast‑track due diligence and verify Evogene’s market, pricing, and competitive assumptions.
Economic factors
R&D-intensive business model across 3 divisions
Evogene’s R&D-heavy model across 3 divisions keeps cash tied up for years, so spending often comes before sales. In 2025, that means funding access and partner cash support matter more than near-term margin, because revenue can lag scientific validation and create working-capital strain.
Each division needs long trials, data, and regulatory steps, so the cost base stays high even when sales are uneven. That makes liquidity the key economic driver: without fresh capital or upfront partner payments, project timing can slip and burn rates rise.
Agriculture demand tied to farmer spending cycles
Evogene Ltd.’s seed traits, biologicals, and crop chemicals sell best when farm income and input budgets are healthy. USDA’s 2025 U.S. net farm income is forecast at $180.1 billion, but crop cash receipts are down 2.1%, so farmers stay selective. Corn, soybean, wheat, rice, and cotton prices still steer adoption, and weak margins usually slow buying.
Exposure to USD, ILS and BRL currency movements
Evogene Ltd.’s mix in Israel, the U.S. and Brazil leaves it exposed to USD, ILS and BRL swings; in 2025, USD/ILS traded roughly 3.5-3.8 and USD/BRL about 5.0-6.0, so even small moves can shift reported revenue and R&D spend. A stronger shekel lifts Israel-based costs in USD terms, while a weaker real can help local expenses but can also distort partner economics in Brazil. For an international R&D and commercialization model, FX can move margins faster than sales do.
Licensing and collaboration revenue dependence
Evogene Ltd. relies heavily on licensing and collaboration income, so milestone fees, royalties, and partner-funded R&D are a key cash-flow buffer. This makes income less tied to product sales, but it also leaves near-term visibility exposed when partner programs slip. For platform firms, slower partner timelines usually mean delayed revenue recognition and weaker quarter-to-quarter predictability.
- Milestones support cash flow.
- Royalties depend on partner launches.
- R&D funding can offset burn.
- Delays cut near-term visibility.
Human health and cannabis markets are capital-sensitive
Human health and cannabis markets are capital-sensitive because microbiome therapies and medical cannabis need heavy clinical, regulatory, and launch spending before revenue starts. When risk appetite for speculative life-science assets tightens, valuations fall, follow-on funding gets harder, and Evogene Ltd. may have to slow expansion or accept more dilution. That makes cash runway and financing timing critical.
- High upfront R&D and approval costs
- Valuation swings hit funding access
- Tighter markets can slow expansion
Evogene’s 2025 story: cash burn, farm income, and FX drive the outlook
Evogene’s 2025 economics hinge on cash, not margin: R&D spend comes before sales, so funding and partner advances matter most. USDA’s 2025 U.S. net farm income is forecast at $180.1B, but crop cash receipts are down 2.1%, which can slow seed and biologicals adoption.
| 2025 factor | Data |
|---|---|
| US farm income | $180.1B |
| Crop cash receipts | -2.1% |
| FX risk | USD/ILS 3.5-3.8 |
USD/BRL near 5.0-6.0 also moves reported costs and partner economics, while slower partner timelines can delay milestone cash and raise burn.
Same Document Delivered
Evogene Ltd. PESTLE Analysis
The preview shown here is the exact Evogene Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.
Sociological factors
Global food-security demand across staple crops
Global food-security pressure keeps demand high for corn, soybean, wheat, rice and cotton, and FAO’s 2025 outlook still points to more than 2.8 billion tons of world cereal output needs. Farmers and governments want higher yields from less land, so resilient seed traits matter more. That supports Evogene Ltd.’s agriculture pipeline, especially tools that hold up in heat, drought and disease.
Rising preference for sustainable farm inputs
Stakeholders are shifting toward biological and lower-residue inputs; biocontrols still make up only about 5% of global crop protection sales, so adoption has room to run. Consumer pressure on food safety and cleaner supply chains is pushing growers and retailers toward greener tools, which supports Evogene’s biologicals and seed-trait pipeline.
Public acceptance challenges for biotech and cannabis
Public acceptance still limits Evogene Ltd.'s biotech and cannabis markets: many consumers stay wary of GM crops and cannabis products until they see safety data, clear labeling, and third-party proof. In the U.S., the FDA has approved only 2 cannabis-derived medicines, which shows how slowly trust builds even after science advances. Adoption usually rises after regulatory green lights and strong real-world evidence of benefit.
Growing awareness of microbiome-based health solutions
Interest in gut health, immune health, and antimicrobial resistance is rising, and WHO says antimicrobial resistance caused 1.27 million deaths in 2019. That shift makes patients and clinicians more open to targeted biological treatments, which supports Evogene Ltd.'s human health programs.
- More demand for gut and immune solutions
- Higher acceptance of biologic treatments
- AMR keeps the issue urgent
Institutional demand for reduced antibiotic and chemical use
Health and agriculture systems are under pressure to cut antibiotic and pesticide use: WHO linked antimicrobial resistance to 1.27 million deaths in 2019, while the EU’s Farm to Fork plan targets a 50% cut in pesticide risk by 2030. Social concern over resistance, residues, and soil harm is shifting buyer demand toward cleaner inputs.
Evogene Ltd.’s biological and microbiome platforms fit this shift, since they aim to replace or reduce chemical dependence in crop protection and productivity.
- Lower residue and resistance risk
- Supports demand for bio-based inputs
Cleaner crop inputs and trust trends favor Evogene’s biologicals
Sociology favors Evogene Ltd. as farmers and buyers push for cleaner, lower-residue inputs; biocontrols are still about 5% of global crop-protection sales, so adoption can keep rising. Public concern over food safety and antibiotic resistance also supports its biological platforms. Trust still matters most, so proof from field results and labels will drive uptake.
| Signal | Data |
|---|---|
| Biocontrol share | ~5% |
| AMR deaths | 1.27M in 2019 |
| EU pesticide cut target | 50% by 2030 |
Technological factors
CPB platform: Computational Predictive Biology
Evogene’s CPB platform is a proprietary predictive biology engine that uses computational tools to identify and guide product discovery. It supports faster screening, broader scale, and lower discovery risk by focusing R&D on the most promising biological targets. This matters for Evogene because it helps turn large data sets into more selective pipeline decisions.
AI and big-data analytics in life-science discovery
Evogene Ltd. depends on AI and large biological datasets to screen microbes, small molecules, and genetic components faster than lab-only workflows. In 2025, that data edge stayed central as the company pushed model-driven discovery across its three core tech engines.
Its advantage rests on better prediction quality, so each new dataset and validated hit improves screening speed and hit rates. If model accuracy slips, the edge narrows fast in a field where rivals also use machine learning.
3 core innovation areas: microbes, small molecules, genetic components
Evogene Ltd.'s three core innovation areas—microbes, small molecules, and genetic components—widen its addressable market across agriculture, human health, and industrial uses. This mix also lowers reliance on any one product format, which can smooth revenue risk as programs shift from discovery to commercial use. The multi-platform model gives Evogene more shots at value creation, but execution across three science stacks also raises R&D complexity.
Digital discovery for seed traits and biological products
Digital discovery lets Evogene Ltd. screen millions of trait and biology candidates in silico before costly lab and field work. That cuts cycle time and lifts hit rates, which matters because a single missed season can delay commercialization by 12 months or more.
- Prioritize faster, cheaper candidates first.
- Reduce wet-lab and field-trial load.
- Speed matters in short crop windows.
Data-driven microbiome and castor-bean programs
Evogene Ltd.’s microbiome and castor-bean work depends on specialized datasets, and the edge comes from linking wet-lab tests with computational prediction. That matters because castor oil contains about 90% ricinoleic acid, so small trait gains can matter in both health and industrial uses.
- Lab validation must confirm model hits.
- Shared data can speed pipeline generation.
- Platform strength can lower repeat R&D costs.
Evogene’s AI Edge: Faster Discovery, Lower R&D Risk
Evogene’s tech edge in 2025–2026 rests on CPB, an AI biology engine that narrows discovery faster than lab-only work. Its three stacks—microbes, small molecules, and genetic components—keep data reuse high and spread R&D risk. The key test is model accuracy: better hits cut wet-lab cost and speed decisions.
| Metric | Data |
|---|---|
| Core tech | CPB AI platform |
| Platform stacks | 3 |
| Castor oil ricinoleic acid | ~90% |
Legal factors
Biotech regulation across the US, Israel and Brazil
Evogene Ltd. faces three different rule sets in the US, Israel and Brazil for R&D, field trials and sales, so one program can need three compliance paths. In Brazil, CTNBio reviews GMO field work and can take up to 90 days for some determinations, while US FDA/USDA and Israel’s health, agriculture and environmental rules can shift launch timing. That timing risk can move partner milestones and cash receipts. Evogene needs one compliance system that tracks all three legal regimes at once.
IP protection for platform and product discoveries
Evogene Ltd.’s value depends on proprietary algorithms, biological know-how, and licensed outputs, so IP protection is a core legal risk. Strong patents and trade secrets help defend partner deals and royalty streams, while weak protection can quickly erode pricing power and commercial leverage.
This matters because the platform is built on hard-to-copy discovery assets, not just physical products. If rivals can replicate key methods or outputs, Evogene Ltd. loses bargaining strength in licensing talks and could face lower margins.
Licensing agreements with BASF, Corteva and Bayer
Evogene Ltd.’s licensing deals with BASF, Corteva and Bayer depend on tight control of rights, milestones and royalty terms. In 2025, this matters even more because platform-based revenue only scales when each partner’s field, territory and IP scope are clear. Any legal dispute or vague language can delay milestone cash and push royalties out.
Medical cannabis compliance via Canonic and Cannbit
In 2026, medical cannabis still faces country-by-country licensing, GMP, and traceability rules, so Canonic and Cannbit need separate approvals for cultivation, processing, and distribution. Legal status can also shift by product class, with some markets allowing only prescription use, which slows rollout and raises compliance cost. For Evogene Ltd., that means expansion speed depends on local regulatory clearance.
- Separate licenses in each market
- Higher quality and distribution costs
- Product class rules can block expansion
Human health programs subject to clinical and safety rules
Microbiome therapies and antimicrobial-resistant infection programs face strict clinical, safety, labeling, and claims rules, so Evogene Ltd. must prove efficacy and manage adverse-event risk before launch.
In the U.S., the FDA can block or delay commercialization if trial design, manufacturing, or product claims do not meet healthcare standards; this is especially critical for human health programs that need clear clinical proof.
For Evogene Ltd., weak regulatory compliance can turn promising science into a stalled asset, while strong data can support faster approvals and cleaner market access.
- Clinical trials must meet safety rules
- Claims need regulatory support
- Labeling is tightly controlled
- Noncompliance can stop launch
Evogene Faces Three-Layer Regulatory and IP Hurdles
Evogene Ltd. must clear different legal regimes in the US, Israel and Brazil for trials and sales, so one program can face three approval paths. Brazil’s CTNBio can take up to 90 days on some GMO decisions. IP protection is key: patents, trade secrets and tight license terms protect partner revenue and royalties. Medical cannabis and health programs still face strict local licensing and clinical rules.
| Legal factor | Key data |
|---|---|
| Brazil GMO review | Up to 90 days |
| Core markets | US, Israel, Brazil |
| Key risk | IP and license disputes |
| Health programs | Strict trial and labeling rules |
Environmental factors
Climate stress across corn, soybean, wheat, rice and cotton
2024 was the warmest year on record, about 1.55°C above pre-industrial levels, and heat, drought and storm swings hit corn, soybean, wheat, rice and cotton yields. This lifts demand for stress-tolerant crops and fits Evogene Ltd.'s pipeline focus on yield under harsh conditions. Climate risk also makes predictive breeding tools more valuable because they can shorten testing and target resilient traits faster.
Lower-chemical farming demand
Lower-chemical farming is gaining pressure as regulators and buyers push for less synthetic input use; the global biopesticides market is forecast to exceed $10 billion by 2027. Evogene Ltd. can benefit through biological products and precision traits that help cut spray volumes and improve crop resilience. That supports its crop-focused units by matching a clear shift in farm spending toward lower-toxicity tools.
Soil, water and land-use constraints
Evogene Ltd. faces a market where agriculture uses about 70% of global freshwater withdrawals, and the UN says up to 40% of soil is degraded. That makes water-saving and soil-boosting products more valuable, especially in large-scale cropping. Resource-efficient traits can cut input use and help farms protect yields under tighter land-use limits.
Industrial applications tied to castor bean sustainability
Castor bean improvement can support renewable industrial feedstocks, especially as manufacturers cut fossil-based inputs. India still drives about 80% of global castor seed supply, so crop yield and oil quality gains matter for scale and supply risk. That can lift interest in Evogene Ltd.’s industrial segment.
- Renewable feedstock demand is rising.
- Supplier sustainability is now a priority.
- Castor genetics can improve supply.
Biosafety and ecological impact scrutiny
Evogene Ltd.’s biological and genetically guided products face tight biosafety checks, because regulators and customers want low ecological risk before deployment. In agri-biotech, field and environmental validation can stretch launch plans by 6-18 months, so approval speed matters. This scrutiny can slow time-to-market, but it also supports trust and adoption.
- Low ecological risk is a buying filter.
- Validation can delay launch by months.
- Responsible deployment supports adoption.
Climate Pressure Boosts Demand for Evogene’s Resilient Crop Traits
Environmental pressure is rising for Evogene Ltd.: 2024 was 1.55°C above pre-industrial levels, and heat, drought and floods are pushing demand for resilient crops and faster trait screening. Agriculture still uses about 70% of global freshwater, while up to 40% of soil is degraded, so water-saving and soil-health traits matter more. Low-chemical farming is also growing, with biopesticides forecast above $10 billion by 2027. Biosafety checks can slow launches by 6-18 months, but they also support trust.
| Factor | Key data | Impact on Evogene Ltd. |
|---|---|---|
| Climate stress | 2024 +1.55°C | Higher demand for resilient traits |
| Resource pressure | 70% water, 40% soil degraded | Stronger case for efficient crops |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.